ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "52d4f6d7-52ad-48f5-92ac-6995d9e1b304"}, "_deposit": {"id": "2015898", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2015898"}, "status": "published"}, "_oai": {"id": "oai:u-ryukyu.repo.nii.ac.jp:02015898", "sets": ["1642838203782", "1642838412624"]}, "author_link": [], "item_1617186331708": {"attribute_name": "Title", "attribute_value_mlt": [{"subitem_1551255647225": "[原著]ATL患者およびHTLV-IキャリアにおけるsIL-2R、IAP およびp40^\u003ctax\u003e抗体の臨床的意義", "subitem_1551255648112": "ja"}, {"subitem_1551255647225": "Clinical Significances of sIL-2R, IAP and p401^tax Aitibody in ATL Patients and HTLV- I Carriers", "subitem_1551255648112": "en"}]}, "item_1617186419668": {"attribute_name": "Creator", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "増田, 昌人", "creatorNameLang": "ja"}]}, {"creatorNames": [{"creatorName": "大城, 一郁", "creatorNameLang": "ja"}]}, {"creatorNames": [{"creatorName": "下地, 忠夫", "creatorNameLang": "ja"}]}, {"creatorNames": [{"creatorName": "高須, 信行", "creatorNameLang": "ja"}]}, {"creatorNames": [{"creatorName": "Masuda, Masato", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ohshiro, Kazuiku", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Shimoji, Tadao", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Takasu, Nobuyuki", "creatorNameLang": "en"}]}]}, "item_1617186476635": {"attribute_name": "Access Rights", "attribute_value_mlt": [{"subitem_1522299639480": "open access", "subitem_1600958577026": "http://purl.org/coar/access_right/c_abf2"}]}, "item_1617186499011": {"attribute_name": "Rights", "attribute_value_mlt": [{"subitem_1522650717957": "ja", "subitem_1522651041219": "琉球医学会"}]}, "item_1617186609386": {"attribute_name": "Subject", "attribute_value_mlt": [{"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "ATL"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "HTLV- I"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "sIL-2R"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "IAP"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "p40^\u003ctax\u003e antibody"}]}, "item_1617186626617": {"attribute_name": "Description", "attribute_value_mlt": [{"subitem_description": "We have assessed the usefulness of using soluble interleukin-2 receptor (sIL-2R), immunosuppressive acidic protein (IAP), and p40^\u003ctax\u003e antibody for making out the subtypes of adult T-cell leukemia (ATL) and for differentiating among ATL patients, human T-cell leukemia virus type I (HTLV- I ) carriers, and normal individuals. We measured these parameters in 51 patients with ATL (21 acute, 3 lymphoma, 18 chronic, and 9 smoldering), 52 HTLV- I carriers, and 30 normal controls. The serum sIL-2R level was $15.0 \\pm 23.6$ ( $mean \\pm standard$  deviation) ×10^3 U/ml in the ATL patients ($22.7 \\pm 26.8$ ×10^3 U/ml in acute and lymphoma ATL,  $2.47 \\pm 1.79 $ ×10^3 U/ml in chronic ATL, $1.17  \\pm 1.13$ ×103 U/ml in smoldering ATL), $0.62 \\pm 0.22$ ×10^3 U/ml in the HTLV-I carriers, and $0.17 \\pm 0.14$ X10^3 U/ml in the normal controls. Serum sIL-2R levels were significantly higher in the ATL patients than in the HTLV- I carriers and normal controls. Serum sIL-2R levels were also significantly higher in the HTLV- I carriers than in the normal controls. In addition, serum sIL-2R levels were significantly higher in acute and lymphoma ATL than in chronic and smoldering ATL. The serum IAP level was  $784 \\pm 346$  $ \\mu $g/ml in acute and lymphoma ATL, which was significantly higher than the levels of $453 \\pm 211$ $ \\mu $g/ml in chronic and smoldering ATL, $389 \\pm 96$ $ \\mu $g/ml in HTLV- I carriers, and $348 \\pm 88$ $ \\mu $g/ml in normal controls. p40^\u003ctax\u003e antibody was positive in 37 of the 51 ATL patients (16 of the 24 acute and lymphoma ATL patients and 21 of the 27 chronic and smoldering ATL patients) and in 28 of the 52 HTLV- I carriers, but was not detected in the normal controls. We conclude that sIL-2R is useful for disting-uishing the different subtypes of ATL and for separating ATL patients, HTLV- I carriers, and normal individuals. IAP is useful to distinguish patients with the acute and lymphoma ATL from those with chronic and smoldering ATL, HTLV- I carriers, and normal individuals. In addition, p40^\u003ctax\u003e antibody is useful to distinguish normal individuals from HTLV- I carriers and ATL patients.", "subitem_description_type": "Other"}, {"subitem_description": "論文", "subitem_description_type": "Other"}]}, "item_1617186643794": {"attribute_name": "Publisher", "attribute_value_mlt": [{"subitem_1522300295150": "ja", "subitem_1522300316516": "琉球医学会"}, {"subitem_1522300295150": "en", "subitem_1522300316516": "Ryukyu Medical Association"}]}, "item_1617186702042": {"attribute_name": "Language", "attribute_value_mlt": [{"subitem_1551255818386": "jpn"}]}, "item_1617186920753": {"attribute_name": "Source Identifier", "attribute_value_mlt": [{"subitem_1522646500366": "ISSN", "subitem_1522646572813": "1346888X"}, {"subitem_1522646500366": "ISSN", "subitem_1522646572813": "0289-1530"}, {"subitem_1522646500366": "NCID", "subitem_1522646572813": "AN10369445"}]}, "item_1617186941041": {"attribute_name": "Source Title", "attribute_value_mlt": [{"subitem_1522650068558": "ja", "subitem_1522650091861": "琉球医学会誌 = Ryukyu Medical Journal"}]}, "item_1617187056579": {"attribute_name": "Bibliographic Information", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "1994", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "55", "bibliographicPageStart": "49", "bibliographicVolumeNumber": "14"}]}, "item_1617258105262": {"attribute_name": "Resource Type", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_1617265215918": {"attribute_name": "Version Type", "attribute_value_mlt": [{"subitem_1522305645492": "VoR", "subitem_1600292170262": "http://purl.org/coar/version/c_970fb48d4fbd8a85"}]}, "item_1617605131499": {"attribute_name": "File", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "download_preview_message": "", "file_order": 0, "filename": "v14p49.pdf", "future_date_message": "", "is_thumbnail": false, "mimetype": "", "size": 0, "url": {"objectType": "fulltext", "url": "https://u-ryukyu.repo.nii.ac.jp/record/2015898/files/v14p49.pdf"}, "version_id": "d3fdf109-57cc-4c89-92ed-65cdd45fce37"}]}, "item_title": "[原著]ATL患者およびHTLV-IキャリアにおけるsIL-2R、IAP およびp40^\u003ctax\u003e抗体の臨床的意義", "item_type_id": "15", "owner": "1", "path": ["1642838203782", "1642838412624"], "permalink_uri": "http://hdl.handle.net/20.500.12000/0002015898", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2010-07-02"}, "publish_date": "2010-07-02", "publish_status": "0", "recid": "2015898", "relation": {}, "relation_version_is_last": true, "title": ["[原著]ATL患者およびHTLV-IキャリアにおけるsIL-2R、IAP およびp40^\u003ctax\u003e抗体の臨床的意義"], "weko_shared_id": -1}
  1. 学術雑誌論文
  2. 琉球医学会
  3. 琉球医学会誌
  4. 14巻1号
  1. 部局別インデックス
  2. その他

[原著]ATL患者およびHTLV-IキャリアにおけるsIL-2R、IAP およびp40^<tax>抗体の臨床的意義

http://hdl.handle.net/20.500.12000/0002015898
http://hdl.handle.net/20.500.12000/0002015898
d736b720-7573-4739-b7b8-4cc14e9b2407
名前 / ファイル ライセンス アクション
v14p49.pdf v14p49.pdf
Item type デフォルトアイテムタイプ(フル)(1)
公開日 2010-07-02
タイトル
タイトル [原著]ATL患者およびHTLV-IキャリアにおけるsIL-2R、IAP およびp40^<tax>抗体の臨床的意義
言語 ja
タイトル
タイトル Clinical Significances of sIL-2R, IAP and p401^tax Aitibody in ATL Patients and HTLV- I Carriers
言語 en
作成者 増田, 昌人

× 増田, 昌人

ja 増田, 昌人

Search repository
大城, 一郁

× 大城, 一郁

ja 大城, 一郁

Search repository
下地, 忠夫

× 下地, 忠夫

ja 下地, 忠夫

Search repository
高須, 信行

× 高須, 信行

ja 高須, 信行

Search repository
Masuda, Masato

× Masuda, Masato

en Masuda, Masato

Search repository
Ohshiro, Kazuiku

× Ohshiro, Kazuiku

en Ohshiro, Kazuiku

Search repository
Shimoji, Tadao

× Shimoji, Tadao

en Shimoji, Tadao

Search repository
Takasu, Nobuyuki

× Takasu, Nobuyuki

en Takasu, Nobuyuki

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利情報
言語 ja
権利情報 琉球医学会
主題
言語 en
主題Scheme Other
主題 ATL
主題
言語 en
主題Scheme Other
主題 HTLV- I
主題
言語 en
主題Scheme Other
主題 sIL-2R
主題
言語 en
主題Scheme Other
主題 IAP
主題
言語 en
主題Scheme Other
主題 p40^<tax> antibody
内容記述
内容記述タイプ Other
内容記述 We have assessed the usefulness of using soluble interleukin-2 receptor (sIL-2R), immunosuppressive acidic protein (IAP), and p40^<tax> antibody for making out the subtypes of adult T-cell leukemia (ATL) and for differentiating among ATL patients, human T-cell leukemia virus type I (HTLV- I ) carriers, and normal individuals. We measured these parameters in 51 patients with ATL (21 acute, 3 lymphoma, 18 chronic, and 9 smoldering), 52 HTLV- I carriers, and 30 normal controls. The serum sIL-2R level was $15.0 \pm 23.6$ ( $mean \pm standard$ deviation) ×10^3 U/ml in the ATL patients ($22.7 \pm 26.8$ ×10^3 U/ml in acute and lymphoma ATL, $2.47 \pm 1.79 $ ×10^3 U/ml in chronic ATL, $1.17 \pm 1.13$ ×103 U/ml in smoldering ATL), $0.62 \pm 0.22$ ×10^3 U/ml in the HTLV-I carriers, and $0.17 \pm 0.14$ X10^3 U/ml in the normal controls. Serum sIL-2R levels were significantly higher in the ATL patients than in the HTLV- I carriers and normal controls. Serum sIL-2R levels were also significantly higher in the HTLV- I carriers than in the normal controls. In addition, serum sIL-2R levels were significantly higher in acute and lymphoma ATL than in chronic and smoldering ATL. The serum IAP level was $784 \pm 346$ $ \mu $g/ml in acute and lymphoma ATL, which was significantly higher than the levels of $453 \pm 211$ $ \mu $g/ml in chronic and smoldering ATL, $389 \pm 96$ $ \mu $g/ml in HTLV- I carriers, and $348 \pm 88$ $ \mu $g/ml in normal controls. p40^<tax> antibody was positive in 37 of the 51 ATL patients (16 of the 24 acute and lymphoma ATL patients and 21 of the 27 chronic and smoldering ATL patients) and in 28 of the 52 HTLV- I carriers, but was not detected in the normal controls. We conclude that sIL-2R is useful for disting-uishing the different subtypes of ATL and for separating ATL patients, HTLV- I carriers, and normal individuals. IAP is useful to distinguish patients with the acute and lymphoma ATL from those with chronic and smoldering ATL, HTLV- I carriers, and normal individuals. In addition, p40^<tax> antibody is useful to distinguish normal individuals from HTLV- I carriers and ATL patients.
内容記述
内容記述タイプ Other
内容記述 論文
出版者
言語 ja
出版者 琉球医学会
出版者
言語 en
出版者 Ryukyu Medical Association
言語
言語 jpn
資源タイプ
資源タイプ journal article
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 1346888X
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 0289-1530
収録物識別子
収録物識別子タイプ NCID
収録物識別子 AN10369445
収録物名
言語 ja
収録物名 琉球医学会誌 = Ryukyu Medical Journal
書誌情報
巻 14, 号 1, p. 49-55, 発行日 1994
戻る
0
views
See details
Views

Versions

Ver.1 2022-02-22 03:31:38.215815
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3